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Abstract 
Reaching the overall goal of eliminating malaria requires halting disease transmission. One approach to blocking 
transmission is to prevent passage of the parasite to a mosquito, by preventing formation or transmission of game-
tocytes. An alternative approach, pioneered in the veterinary field, is to use endectocides, which are molecules that 
render vertebrate blood meals toxic for the mosquito vector, also killing the parasite. Field studies and modelling sug-
gest that reducing the lifespan of the mosquito may significantly reduce transmission, given the lengthy maturation 
process of the parasite. To guide the development of new endectocides, or the reformulation of existing molecules, it 
is important to construct a framework of the required attributes, commonly called the target candidate profile. Here, 
using a combination of insights from current endectocides, mathematical models of the malaria transmission dynam-
ics, and known impacts of vector control, a target candidate profile (TCP-6) and a regulatory strategy are proposed 
for a transmission reducing agent. The parameters chosen can be used to assess the potential of a new medicine, 
independent of whether it has classical endectocide activity, reduces the insect and parasite lifespan or any combina-
tion of all three, thereby constituting an ‘endectocidal transmission blocking’ paradigm.
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Background
Eradicating malaria: thinking about preventing 
transmission in addition to treatment options
Malaria remains one of the leading causes of morbidity 
and mortality, with an estimated 435,000 deaths in 2017, 
93% of which were in Africa [1]. Between 2010 and 2016, 
the incidence of malaria infection decreased by 18%. This 
prevention of infection was largely driven by the deploy-
ment of insecticide-treated nets (ITNs), indoor residual 
spraying (IRS), and the introduction of high quality 
treatments, which show a significant ‘post-treatment 
prophylaxis’ [2]. Recently, there has also been a dra-
matic increase in the deployment of medicines to protect 
vulnerable populations, including seasonal malaria chem-
oprevention (SMC) for children under 5 years of age [3, 
4] and intermittent preventive treatment in pregnancy 
(IPTp, [5]). Over the same period (2010–2016), there 
has been an even larger decrease in the mortality rate, 
32% [1]. This difference points to increased survival of 
infected individuals, which can be attributed to better 
case management. Key factors here are the more wide-
spread use of diagnostics, wider availability of high-qual-
ity, fixed-dose artemisinin combination therapy (ACT, 
[6]), and the switch to injectable artesunate treatment 
of severe malaria. In 2015, the World Health Organiza-
tion (WHO) announced its global technical strategy for 
malaria for 2016–2030, which sets an ambitious target 
of reducing malaria incidence and mortality by a further 
90% [7]. This strategy has two major pillars, the first of 
which is to ensure universal access to malaria prevention, 
diagnosis and treatment, and the second, to accelerate 
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efforts towards malaria elimination. To achieve this, it 
will be important to continue the investments to develop 
new generations of all the interventions described above, 
particularly for vector control and case management.
Basic concepts of malaria transmission control
The theoretical analysis of disease eradication can be 
summarized as the need to reduce the number of sec-
ondary infections coming from an initial infection in a 
fully susceptible population, to the extent that transmis-
sion is eventually halted. This is described as the basic 
reproduction number,  R0 [8]. Only by reducing  R0 to < 1 
over extended transmission cycles can local elimination 
be achieved. In its simplest early form, the basic repro-
duction rate is defined by six parameters in the following 
equation:
Three parameters relate to the mosquito vector: m, 
the number of mosquitoes per human host; 1/µ, the life 
expectancy of the mosquitoes (µ is a measure of daily 
mortality); and a, the rate of biting humans. Two param-
eters describe the life cycle in the human host: b, the 
transmission efficiency from mosquitoes to human; and 
1/r, the duration of the disease in humans (r is a measure 
of recovery rate of infected people). Finally, two param-
eters describe the infection of mosquitoes by humans: c, 
the transmission efficiency from human to mosquito, and 
once again a, the rate of the mosquitoes biting humans.
One approach to transmission blocking is ITNs. Ferti-
lized female mosquitoes of the genus Anopheles require 
a blood meal to successfully produce eggs, and typically 
seek out humans between dusk and dawn. ITNs provide a 
lethal barrier, preventing mosquitoes from biting humans 
and killing the insects [9]. Insecticides used in today’s 
ITNs mostly belong to the pyrethroid class [10], although 
second-generation nets under consideration include 
those with additional actives, such as the pyrrole, chlor-
fenapyr [11], the synergist, piperonil-butoxide [12], or the 
insect growth regulator, pyriproxyfen [13]. By preventing 
biting, these nets ensure blood-feeding inhibition (BFI) 
in addition to killing the mosquitoes, where the vectors 
are still susceptible. Another approach is IRS. Blood-fed 
mosquitoes typically rest on indoor wall surfaces, dur-
ing which time they release excess liquid and regain full 
flight capacity, or stay longer to digest their blood meals 
to gravid status. Unfed mosquitoes may also temporarily 
rest on the wall surfaces. These resting mosquitoes can be 
targeted to different degrees by IRS. Both ITNs and IRS 
therefore lower the number of mosquitoes, m, the rate 
of biting a, but most importantly the daily survival prob-
abilities and therefore life expectancy of the mosquitoes, 
R0 =
a2bcm
rµ
1/µ. However, resistance has now been observed to all 
the classes of insecticides used both in ITNs and IRS [14], 
meaning that the full value of these interventions is heav-
ily compromised. In such cases, pyrethroid-treated ITNs 
may still provide a physical barrier (reducing the biting 
rate) and limited toxicity, even among resistant insects, 
so at least the personal protection is retained even when 
the communal benefits usually associated with the killing 
effect of nets are lost. However, resistance heavily com-
promises the protective value of IRS [15], and there has 
been a significant decline in the use of IRS over recent 
years. In addition to the evolution of insecticide resist-
ance, mosquito populations in Africa are changing their 
behaviour to avoid the indoor environment [16–19], 
with an increasingly significant proportion of biting now 
occurring outdoors and early in the evenings [20–23].
New approaches are therefore urgently needed to 
complement ITNs and IRS for vector control. Attractive 
targeted sugar baits (ATSB) are one approach where an 
insecticide is incorporated in a membrane-bound sugar 
bait to attract and kill mosquitoes, typically placed just 
outside houses, thus reducing transmission at the popu-
lation level [24]. An alternative approach is the gene-
drive approach, where genetically engineered insects 
carry a sterility gene, and spread it to the population 
[25], or where the Anopheles are engineered to become 
refractory to Plasmodium infections [26]. Multiple other 
options, with different levels of evidence  for success, 
have been proposed, including expansion of larval source 
management, use of area-wide spatial repellents either 
alone or in combination with traps to form push–pull 
systems, improved housing, use of entomopathogenic 
fungi, and use of endectocides among others (reviewed in 
[27]).
Current case management of malaria patients may leave 
significant gametocytaemia
Clinically, transmission can be reduced either by 
decreasing the number of gametocytes in a patient, or 
decreasing their ability to be transmitted, thus lowering 
the proportion of infective bites, b. Existing anti-malar-
ial treatments differ significantly in their capacity to 
reduce gametocyte carriage, because they were primar-
ily developed to kill blood-stage parasites, and game-
tocytes produce no symptoms. A recent meta-analysis 
of 121 trials found that the prevalence of gametocyte-
carrying patients dropped six-fold after ACT [28], but 
there was no association between the rate of asexual 
parasite clearance and gametocytaemia during follow-
up. All new pre-clinical development candidates in the 
global malaria portfolio (http://www.mmv.org; [29]) 
are now routinely tested for their transmission-block-
ing activity as assessed by standard membrane feeding 
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assays (SMFAs; [30]), but case management is unlikely 
to greatly impact malaria transmission for the moment.
Endectocides used in transmission blocking
A remaining possibility is the idea of giving a drug to an 
infected individual that results in the death of the arthro-
pods feeding on them. Endectocides have been com-
monly used in veterinary practice to reduce or eliminate 
ticks in companion animals, such as Ctenocephalides 
felis in cats and multiple species of ticks (Rhipicephalus 
sanguineus, Ixodes ricinus, Dermacentor reticulatus) in 
dogs. These treatments are mainly aimed at the parasites 
that these ticks transmit. Lyme disease in humans is the 
result of infection by the tick-borne spirochete Borellia 
burgdorferi, and many more human tick-borne diseases 
have been described [31]. Although Lyme disease is typi-
cally treated by 14–21 days of antibiotic treatment, early 
administration of an endectocide, ivermectin, could be 
beneficial in some settings. Studies with fluralaner [32] in 
dogs have shown 100% mortality of the tick within 12 h 
after oral treatment, which would be sufficiently fast to 
potentially prevent the primary infection by Lyme dis-
ease. A recent study has also highlighted the potential for 
repurposing the isoxazolines, fluralaner and afoxalaner 
to kill mosquito vectors for malaria and dengue [33]. 
In human medicine, ivermectin is used to kill the para-
sites in patients infected with the mite Sarcoptes scabiei, 
which results in scabies [34].
When the parasites that vectors spread are the more 
relevant target, rather than the vectors themselves, the 
relation between drug exposure and how this shortens 
the lifespan of the insect becomes particularly relevant 
for malaria transmission [35–39]. Even under optimal 
climatic situations, Plasmodium falciparum requires 
10–12 days for its gametes, once taken up by mosquitoes, 
to produce infectious sporozoites [40]. The natural lifes-
pan of the mosquito is typically 1–2 weeks, so shorten-
ing the lifespan of the insect may prevent the formation 
of infectious sporozoites, and provide powerful trans-
mission-blocking opportunities. Clearly, the transmis-
sion-blocking activities of new drugs in the insect stages 
includes several options for shortening the host and par-
asite lifespan, and moves the discussion beyond the clas-
sical definition of an endectocide. It would seem easier to 
use medicines that ‘merely’ prevent the differentiation of 
gametocytes into sporozoites, as opposed to those that 
kill the entire insect; however there are only examples 
of the latter, and drugs that specifically target sporozoite 
development are very difficult to discover, so this review 
focuses on the classical endectocides, although the new 
TCP-6 covers additional scenarios.
The experience of ivermectin use in preventing malaria 
transmission
Over recent years there has been growing interest in 
the use of ivermectin, as a potential endectocide, for a 
use in malaria. Several clinical studies have been con-
ducted, [35, 41–45], and the WHO has published a 
Meeting Report on Ivermectin for malaria transmission 
control [46]. The definition of the Target Product Pro-
file does depend on the proposed deployment; and this 
report focused on the use case for high-dose ivermectin 
as a stand-alone mass drug administration (MDA) regi-
men. This initial research has suggested that the relatively 
short human plasma half-life of the molecule (approxi-
mately 12–36  h) may require a much higher dose or 
more frequent administration than the standard single 
150–200 μg/kg used in helminth control, or long-acting 
formulations, such as recently demonstrated in Tanza-
nia, where efficacies in cattle lasted over 6 months [47]. 
The alternative approach would be to use ivermectin in 
combination with other malaria control modalities. In 
another example from Tanzania, addition of ivermec-
tin to long-lasting, insecticidal-treated bed nets (LLINs) 
resulted in a near-complete collapse of populations of the 
malaria vector, Anopheles arabiensis, inside large natural-
ized mesocosms [48]. Combining ivermectin with SMC 
is another option, where 3  days of ivermectin could be 
given each month with a full treatment course of anti-
malarials [49, 50]. This also underscores an additional 
risk in use of endectocides in malaria elimination; the 
possibility that insects could emerge which are no longer 
sensitive to ivermectin, as is seen for other targeted 
arthropods [51] and helminths [52]. In this case, it is 
always important to consider these endectocides as com-
plementary to other vector control interventions (such as 
LLINs or IRS) that use insecticides that remain effective 
even against ivermectin-resistant mosquitoes.
A target candidate profile for endectocidal transmission 
blocking in malaria
This paper explores the use case for an ideal medicine 
for blocking transmission through endectocidal activity. 
This requires a definition of the ‘use case’, the way such a 
medicine would be deployed, and several are in discus-
sion: MDA as a stand-alone therapy, inclusion with SMC 
regimens, or in addition to treatment regimens, all three 
use cases being complementary to core vector control 
interventions such as ITNs or IRS. The requirement for 
such uses would be described in a target candidate profile 
(TCP) that includes comments about formulations, and 
combinations required for the ideal product.
TCPs have been developed for other types of anti-
malarial medicine, and help define the screening cascade, 
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and the supportive data required [53]. Profiles for com-
pounds which address blood-stage asexual parasites 
(TCP-1), relapse of the dormant hypnozoites (TCP-3), 
hepatic schizonts (TCP-4), and transmission blocking via 
gametocytes (TCP-5) have been previously defined [53]. 
In this review, a new target candidate profile, TCP-6, is 
described for an endectocide, where the reference mole-
cule is currently elevated-dose ivermectin. The definition 
of the endectocide in this case is expanded to include 
existing examples that kill blood-feeding Anopheles, 
and the concept that it is actually also a transmission-
reducing and transmission-blocking agent. Following 
the development of the TCP, there is a discussion of the 
development and regulatory pathway. Even for molecules 
that are currently on the cusp of preclinical development, 
such as the isoxazolines, regulatory approval for use in 
adults and children may take 8–10  years. Given these 
very long time-horizons, it is essential to have a clear 
vision of how to proceed, and a widely agreed frame-
work, but with the understanding that new evidence may 
necessitate adjustments of such frameworks and path-
ways. The proposal of the endectocidal transmission-
blocking molecule TCP-6 is made in full knowledge that 
this will be modified in the light of new data.
General outline of the TCP‑6 profile
When considering the features proposed in a new TCP-6 
(outlined in Table  1) it is important consider the use 
case. Compounds developed for TCP-6 use in combi-
nation with SMC are ideally required to still be present 
in human blood at day 28 after administration at a con-
centration sufficient to decrease the mean lifespan of 
malaria-competent female Anopheles that take a blood 
meal, since this is also the administration period for 
SMC. This, and the requirement to minimize the dose 
size requires that the intrinsic potency of a new TCP-6 
molecule should be high, with, ideally, clear activity in 
the nanomolar range. Poor potency may result in high 
dosing (> 10  mg/kg), difficulties in co-formulation with 
other anti-malarials, problems when formulating fixed-
dose combinations, and high cost of goods. Therefore, 
during the lead optimization work, the optimization of 
potency and pharmacokinetics will need special atten-
tion. Second, a faster-acting compound is preferred, 
which will be linked with the mechanism of action and 
the mosquito tissue distribution. There is a risk of trans-
mission in a malaria-endemic region with every blood 
meal. Any compound that is long-lasting in the verte-
brate host but is able to dramatically decrease mosquito 
survival to fewer than 10  days post mosquito infection 
(the estimated extrinsic incubation period of Plasmo-
dium) will be particularly effective as they would stop 
pathogen development in the mosquito-midgut [40]. Any 
compound able to kill rapidly and thus reduce egg lay-
ing, as already demonstrated with some formulations of 
ivermectin when administered to cattle [43] and humans 
[48], will also greatly impact the vector population. Third, 
since a new compound with pure TCP-6 activity targets 
the mosquito rather than the human, and the initial use 
case involves children, the safety and tolerability pro-
file need to be extremely convincing, with a wide safety 
margin. There are, in fact, safety concerns with ivermec-
tin [54]. An alternative is to consider these endectocide 
transmission-blocking candidates primarily for use in 
adults, in which case communal benefits are still accru-
able even by children.
Use cases: how could an endectocide be deployed 
for transmission blocking?
Three types of use case can be envisaged. The first is as a 
stand-alone medicine to be used in MDA, the second as 
an adjunct to treatment with ACT or the successors, and 
the third as part of the SMC regimen, again all backed by 
effective vector control with LLINs or IRS.
Although the ‘stand-alone’ MDA route initially appears 
to be the most interesting, it is limited since medicines 
cannot be given to women of unknown pregnancy sta-
tus in the absence of significant additional clinical safety 
data. For example, in the case of artemether-lumefan-
trine, such a compelling data package on safety in the 
first trimester of pregnancy is only starting to emerge two 
decades after the launch of that treatment [55]. For new 
chemical entities, especially those conferring no direct 
benefit, a more conservative approach is warranted.
The second approach (using in conjunction with ACT) 
is an option, but currently the majority of infections in 
Africa are asymptomatic. Unless the guidance on treat-
ment is extended to include asymptomatic infections, 
then this route will also be limited.
The third approach builds on the success of SMC. 
In its current implementation, SMC is the use of a full 
treatment course of sulfadoxine–pyrimethamine and 
amodiaquine (SP–AQ) to each child aged between 
3 and 59  months administered monthly for three or 
four  months throughout the rainy season in areas of 
highly seasonal malaria. SMC has been enormously 
successful in reducing the incidence of clinical malaria 
infection and deaths in the Sahel [56], with over 13 mil-
lion children protected in 2016. Unfortunately, because 
of parasite resistance, there are no effective drugs for 
SMC in areas south of the Sahel [57]; this is a gap which 
a TCP-6 molecule could fill. Currently, there are discus-
sions to extend the Senegalese programme, to include 
children up to menarche, a concept known as the ‘Sen-
egalese Ladder’ [4]. Because of the combination of high 
infection frequency, low immunity and relatively large 
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body surface area children in the age range 6–10  years 
old are the principal source of transmission [58], with 
those in the age bracket 5–15  years contributing about 
the same as all older than 15  years [59]. For exam-
ple, modelling studies on ivermectin show that with an 
increased dose (300 µg/kg daily for 3 days, every month 
throughout the rainy season [49], rather than a single 
150 µg/kg dose) a significant additional decrease in inci-
dence of clinical malaria can be obtained when given 
with SMC up to the age of 10  years (HS, unpublished 
observation). Broader population coverage is, therefore, 
clearly expected to have a greater impact on population 
incidence of infection. However, this requires evidence of 
safety in first-trimester pregnancy. Thus, a new molecule 
should be non-teratogenic.
Demonstration of efficacy of an endectocide in reduc-
ing incidence rates of symptomatic malaria when added 
to SMC could then be followed by measurements of the 
impact on asymptomatic malaria, or even parasite preva-
lence. The initial modelling suggests that treating only 
children under 10  years of age would provide a signifi-
cant reduction in mosquito survival and impact parasite 
prevalence in the wider population (see Fig. 1), and this 
is proposed as a Phase II study. Demonstration of popula-
tion efficacy requires larger cluster-randomized studies, 
which have significant logistical challenges, and so this is 
reserved for the pivotal Phase III intervention (see below 
for outlines of the clinical studies).
The deployment of an endectocide would need to be 
part of a public health agenda, and therefore the high-
level customers are the health ministries, the national 
malaria control programmes and the national vector-
borne disease programmes. Therefore, four factors are 
critically important: a demonstration of safety in the 
targeted populations, the ease of deployment, a clearly 
visible early-stage benefit and appropriate cost/benefit, 
given the scale of deployment necessary. Cost is a criti-
cal factor: bearing in mind that SMC costs US$0.30 per 
month, and treatment with an ACT is less than $0.50 for 
children, a price target of $0.50 per month has been set, 
considerably lower than the $1.50–6.00 per day cited in a 
TCP for ivermectin [46].
TCP‑6 requirements are based on their impact 
on transmission as predicted by modelling
The impact of endectocidal transmission-blocking 
was assessed using an existing transmission model of 
malaria [58, 60, 61]. Here the impact of dosing a TCP-6 
compound in conjunction with the current gold stand-
ard for SMC was measured on the incidence of clinical 
malaria and parasite prevalence in children 0–10  years 
of age. These simulations have allowed for the cover-
age of the population dosed, population characteristics, 
transmission intensity, and the shape of the hazard ratio-
duration curve. Modelling suggests targeting a haz-
ard ratio of 4 at day 30 as appropriate, with simulations 
suggesting that above this there is minimal additional 
impact. A hazard ratio of 4 means that a mosquito has 
a 4 times higher daily probability of mortality compared 
to a mosquito that has not taken a blood meal contain-
ing a TCP-6 compound. In the modelling, a conserva-
tive profile is used, where no additional benefit is given 
for the (early) period where the hazard ratio is above 4, 
hence the flat appearance of the curve in the first graph 
of Fig. 2. A coverage of 80% of the intended SMC popu-
lation along with SMC for four successive months (in 
children 6 months to 10 years old in regions with para-
site prevalence of 7–62%), would deliver substantial 
reductions in clinical incidence. The observed reductions 
range between 70 and 90% and 40 and 60%, respectively 
[49], depending on the transmission intensity category 
(Fig.  3). Interestingly, clinical studies that examined the 
ivermectin impact on mosquito survival (when dosed at 
3 × 300  μg/kg), based on feeding assays post-dose, have 
shown that the hazard ratio is 4 at day 14 but only 1.1 at 
day 30 [49], but even with this inferior profile ivermectin 
is still predicted to effect a significant reduction in rate 
of clinical incidence when used in combination with SP–
AQ. This suggests that a dose producing a hazard ratio of 
4 at day 14 may suffice, reflecting the possibility that the 
survival times of mosquitoes exposed to the drug may be 
disproportionally shortened in the wild.
Protecting against the development of resistance
The mosquito resistance risk against a new TCP-6 
molecule needs to be acceptable. WHO guidelines 
require that for a susceptible mosquito population, 
new insecticides must deliver 98% mortality within 
24 h of contact [62]. Mosquitoes surviving such insec-
ticide contact have an increased risk of developing 
resistance at the population level. Ivermectin has con-
siderable benefits at concentrations significantly lower 
than the  LC95 (the lethal concentration for 95% of the 
mosquito population) at day 30 post-dosing, due to 
the decreased fitness and survival of mosquitoes hav-
ing ingested ivermectin [35]. Determining the precise 
level of the resistance threat which is acceptable for 
an endectocidal transmission-blocking strategy will 
be difficult, but should not discourage development 
of this product class, especially since emergence and 
spread of such resistance could be managed by effec-
tive combinations with other vector control tools [63]. 
There is currently insufficient data to determine the 
degree of fitness reduction from a sub-lethal concen-
tration of different endectocides, though it is likely 
that such a relationship is mechanism-dependent. 
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Fig. 1 Representative simulations in regions with differing transmission intensities. Four scenarios are considered. In blue, 80% coverage of SMC 
in under 5 year olds, with no TCP-6 compound and only SP–AQ; in red 80% coverage of SMC under 10 year olds with no TCP-6 compound and 
only SP–AQ; in dark blue 80% coverage of SMC and a TCP-6 compound in all children under 5; and in magenta 80% coverage of SMC and a TCP-6 
compound in all children under 10. The clinical case incidence of symptomatic malaria on the Y-axis for the left-hand figures is the incidence in 
children 0–10 years of age. The PCR-measured prevalence on the Y-axis for the right-hand figures is in all age groups
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Resistance to pyrethroids used in common current 
vector control interventions is often a result of Cyp 
P450 overexpression, and does not typically result in 
a fitness penalty. Thus, a drug targeting TCP-6 should 
have a different mode of action of resistance to insecti-
cides in ITN and IRS products used in the target com-
munities. This provides an additional safeguard against 
the emergence and spread of resistance, which may be 
sufficient to underpin the use of a single endectocide, 
rather than a combination.
Safety and tolerability of a new endectocidal 
transmission‑blocking strategy
The new drug may not produce an immediate benefit, 
in terms of protection from malaria for the individuals 
enrolled in a treatment campaign, although there will be 
some effects on other ectoparasites and helminths. Such 
Fig. 2 Impact of a TCP-6 compound on mosquito survival, assuming that the compound can maintain a hazard ratio of 4 up until day 30. The 
model assumes that a mosquito lives for 50 days in the laboratory and for 10 days in the wild. The panel on the right shows the HRs (the ratio of the 
blue and red lines in the middle and right graphs) plotted over the time expected of the TCP6 lasting in the blood for 30 days
Fig. 3 Percentage reduction in clinical incidence of symptomatic malaria in children < 10 years old (left panel) and annual PCR prevalence in all 
ages (right)
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a medicine would be viewed as altruistic, and the ethi-
cal context would be similar to that previously discussed 
for transmission-blocking vaccines [64, 65]. There are 
experimental approaches to transmission-blocking vac-
cines [66, 67], with the most advanced candidate being in 
clinical testing [68]. The safety and tolerability for a new 
TCP-6 molecule needs to be at a similar level to that tra-
ditionally seen in vaccination programmes. Tolerability 
is very important here, especially the risk of vomiting, 
since the compound would be given concomitantly with 
other medication. This places restrictions on the total 
mass of the drug, but also underscores that the formula-
tion must be child-friendly. The use in combination with 
SMC means that the clinical development programme 
will need to focus on specific drug–drug interactions, 
especially any that may adversely impact the risk/ben-
efit ratio of the new TCP-6 molecule. Beyond the stand-
ard focus on serious and severe adverse events, as in any 
drug development programme, specific attention will be 
given to early signal detection for risk of life-threatening 
adverse events, such as drug-induced anaphylaxis, Ste-
phens-Johnson Syndrome, liver/renal injury, arrhythmias 
or aplasia. In reality, confidence that such events do not 
even occur at low frequencies will require continuous 
pharmacovigilance, and the threshold risk/benefit bal-
ance tolerated is likely to be extremely low.
Given that a critical success factor is deployment in as 
wide an age range as possible, it is important to know if 
the safety profile potentially allows development for use 
in pregnancy and children. If no non-clinical signs of 
developmental and reproductive toxicology are observed 
in two preclinical mammalian species with a completely 
new TCP-6 compound, inclusion of women of childbear-
ing age might be permitted in clinical studies. However, 
a large safety database, most likely from accidental expo-
sure in early pregnancy would be required prior to the 
use of such an agent in larger population use cases, such 
as in MDA.
Approaches to finding new TCP‑6 candidates
Screening strategies
Screening efforts to find new endectocides have moved 
from in  vivo screens to in  vitro screens in the last two 
decades, highlighted by the early work on avermec-
tins, and more recent work on isoxazolines. In  vitro 
and in  vivo screening systems have been developed 
using membrane feeding assays, known as the ‘artificial 
dog’ because of their use in rearing fleas for experimen-
tal purposes [69]. These have been used to character-
ize the activity of molecules on commercially important 
ectoparasites in the absence of a molecular target assay 
[69]. The artificial membrane system was used to iden-
tify and optimize new scaffolds, such as derivatives of the 
fungal metabolite nodulisporic acid A [70], and charac-
terize over 3000 compounds in the development of the 
isoxazoline, sarolaner. As with any phenotypic screening 
programme, this work was eventually supported by data 
from inhibition of the molecular target in stable cell lines 
expressing cat flea RDL (resistance-to-dieldrin) genes for 
assessment of the GABA-gated chloride channel [71].
Primary screening of compounds by the IVCC (Inno-
vative Vector Control Consortium) and partners over 
the last few years has allowed the assessment of some 4 
million compounds as insecticides. However, these have 
been screened as part of a search for new insecticides for 
ITNs or IRS, focusing on compounds that are active upon 
contact with the mosquito. The delivery of an insecticide 
through oral ingestion provides the potential for the use 
of other chemistries, including those that do not depend 
on the uptake through the insect tarsi. Here, the more 
relevant comparator is the search for new molecules for 
use in ATSBs [24], since in both cases the molecule is 
ingested by the mosquito. However, there are still key dif-
ferences in the properties required: a TCP-6 is required 
to be orally available in humans and have very high safety 
and tolerability, whereas an ATSB insecticide just needs 
to be stable and soluble in the sugar matrix. In practice, 
the insecticide doses ingested by the insect via these two 
routes (ATSB or as a TCP-6) will differ vastly, so potency 
will need to be higher in the latter case.
Another source for potential TCP-6 candidates comes 
from repurposing advanced compounds from the com-
panion animal endectocide/insecticide portfolio. A 
recent internal review of the available data by Medicines 
for Malaria Venture (MMV) and IVCC identified around 
200 known insecticides and endectocides; these are cur-
rently being assembled into a collection for screening.
A process for the characterization and optimization of TCP‑6 
candidates
The process of screening and compound optimization 
is described below and in Fig. 4, and is aligned with that 
described previously for malaria and other neglected 
diseases [72]. This cascade has a number of critical 
components:
a. The gold standard assay here is the standard mem-
brane-feeding assay (SMFA), in which female 
Anopheles (typically Anopheles stephensi) feed on a 
blood meal in the presence or absence of test com-
pounds. The SMFA is a relatively resource-intensive 
assay, but recent set-ups that use blood containing 
DNA barcode-labelled bacteria allows the SMFA to 
be run in a 96-well format [73]. This assay can be 
used to compare test compound activity as part of 
a sugar bait or in a blood meal, to thus establish the 
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relative potential in an ATSB or as a TCP-6. In this 
assay, the end-point is mortality over time, which can 
then be expressed statistically using hazard ratios. 
Once efficacious compounds are identified, a second 
SMFA could be performed using Stage V gameto-
cyte-infected human blood, to examine concentra-
tion effects on subsequent oocyst prevalence. This 
allows an optional secondary endpoint that explores 
whether a TCP-6 also blocks transmission at concen-
trations below that required for mosquitocidal activ-
ity.
b. The next stage is to demonstrate adequate potency 
against the main malaria-transmitting Anopheles 
species in Africa: Anopheles gambiae, Anopheles 
coluzzii, Anopheles arabiensis, and Anopheles funes-
tus. At this stage, adding broader secondary screen-
ing assays including other insect vectors (Aedes 
species) as well as ticks and lice would give valuable 
information for uses outside malaria.
c. Once potency across laboratory species has been 
confirmed, efficacy against highly insecticide-resist-
ant field mosquitoes is evaluated. The SMFA will 
need to be adapted to use field mosquitoes. Mos-
quito resistance is typically due to: up-regulation of 
P450 s, enhancing toxin metabolism; cuticle thicken-
ing, which lowers the permeability of the toxin to the 
site of action; or mutation of the specific mosquito 
biological target [74]. It is important to note that an 
ATSB and TCP-6 with the same mechanism of action 
or resistance could still be complementary rather 
than competing tools, when used with each other in 
accordance with best practice for insecticide resist-
ance management, and other standard measures in a 
particular region.
d. The life cycle fingerprint of such a compound 
would need to be established, by testing for inhibi-
tion against all stages of the Plasmodium life cycle. 
Any activity against the asexual blood or liver stages 
would be particularly beneficial, since such patient 
benefit would potentially simplify the clinical devel-
opment plan.
Fig. 4 Screening cascade for identifying compounds for TCP-6 or ATSB. The bottom box identifies the suite of studies necessary for full evaluation 
of a potential TCP-6 candidate drug. If any properties require optimization, then medicinal chemistry would be driven using the A. stephensi SMFA to 
assess potency alongside any of the other relevant non-efficacy assays
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e. Potential TCP-6 agents will also be tested for any 
repellent effects; this can be done through a choice 
test between TCP-6-containing blood versus 
untreated blood. Clearly, repellent activity in such an 
agent is undesirable.
Beyond these components, the optimization of an 
endectocide is similar to any other drug, with consid-
erations that the drug will be used primarily as a vector 
control tool. The focus should therefore be on balanc-
ing potency, pharmacokinetics, pharmacodynamics, and 
safety. The preclinical candidate will need to have appro-
priate solubility, permeability and pharmacokinetics to 
give confidence that the predicted human pharmacoki-
netics in the target population with the proposed dose 
are sufficient to support monthly dosing. These predic-
tions would initially be based on in  vitro data, but sup-
ported by in vivo studies in rats and dogs. For an existing 
insecticide the toxicology part of its regulatory dossier 
will provide much information about metabolism and 
clearance of the active ingredient in mammalian systems. 
Ideally the regimen would consist of a single dose, with a 
potential for three daily doses in line with current SMC. 
The requirements for high oral bioavailability and low 
human clearance place a particular demand for this TCP. 
The non-clinical safety package is similar to that for any 
other oral candidate drug [75]. These include off-target 
pharmacology, ion channel inhibition including hERG 
(human Ether-a-go-go-Related Gene), in  vitro genotox-
icity including Ames and micronucleus tests, and pho-
totoxicity studies. The required exploratory non-GLP 
(Good Laboratory Practice) rat safety study to support a 
clinical candidate would be a 14-day study, plus at least a 
7-day wash-out period to examine reversibility. Because 
of the need for TCP-6 compounds to be well tolerated, if 
the biological target in the mosquito is known and ortho-
logues exist in humans, then exquisite selectivity may be 
required. Finally, a coherent picture of the intellectual 
property position, including access to existing safety data, 
will be needed to establish responsibilities moving for-
wards [76].
The regulatory strategy for a new TCP‑6
General considerations
The outline for a TCP-6 clinical development strategy 
is based on the initial use of the compound as part of a 
SMC campaign. Use in combination as an add-on to 
an ACT for MDA or as a tool for malaria control and/
or elimination could build from this initial application. 
Irrespective of the targeted use case, the regulatory reg-
istration of the new compound must first be achieved. 
Any new compound will be developed with a view to 
obtaining stringent regulatory approval or opinion with 
the US FDA or EMA (European Medicines Agency) as 
a first step. This would subsequently lead to WHO-Pre-
qualification and facilitate National Regulatory Authori-
ties approval in malaria-endemic countries.
No drugs are currently approved for such a transmis-
sion-blocking strategy; hence no precedent can serve as a 
basis for the regulatory path. Discussions with regulators 
as well as the various WHO stakeholders will be essen-
tial at the early stages and all along the development to 
validate the initial concept and overall development plan 
to achieve registration. Since the current reference, iver-
mectin, is widely used as a human medicine, this new 
class, endectocidal transmission-blocking compounds, 
will likely be regulated through the medicines prequali-
fication pathway, rather than the vector control prequali-
fication route, even if the candidates primarily act on the 
vectors. The widespread use of ivermectin, and the avail-
able safety database may support an abbreviated pathway, 
but even in this case, there will need to be significant 
additional data given the increased dose and duration 
proposed.
Thus, a new indication of ‘transmission-reducing agent’ 
is proposed. This agent would be added on top of the gold 
standard SMC regimen SP–AQ as an initial exemplar. 
SP–AQ was granted WHO-Prequalification, is registered 
in endemic countries, and is currently recommended by 
the WHO for use in  SMC in children under 5  years of 
age in the sub-Sahel region. As discussed earlier, there 
is interest in extending SMC to 5–10  year olds, as is 
already the case in Senegal, due to the increasing burden 
of malaria in this age group [4]. This add-on approach 
could be applicable to other, future approved treatment 
combinations.
The clinical efficacy endpoints proposed for Phase II 
and III for a TCP-6 that is added on top of SMC would 
measure incidence rate reduction in symptomatic 
malaria, with entomological endpoints being proposed 
as supportive endpoints. Collecting the secondary ento-
mological endpoint data may also be useful in building 
evidence of the relationship between entomological and 
clinical endpoints. This will support the future use of 
entomological endpoints, ideally as surrogate endpoints, 
when evaluating TCP-6 on top of MDA with ACT later 
on.
An outline clinical development plan for a novel 
TCP-6 added to SP–AQ for SMC in asymptomatic sub-
jects < 10 years of age is proposed in Fig. 5. In the future, 
additional or alternative SMC combinations will be likely 
replacements of SP–AQ, though the present discussion 
focuses on today’s gold standard.
Initial estimates of the relationship between drug con-
centrations and mosquito mortality will be provided 
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through in vitro assessments, which in conjunction with 
initial predictions of the human pharmacokinetic profile 
will guide early clinical development by providing an ini-
tial indication of the likely dose range, including whether 
the target exposure duration is likely to require a 3- or 
1-day dosing regimen.
Phase I design
In Phase I, the safety and tolerability of the compound 
will be assessed in parallel with assessments of mosquito 
mortality using direct feeding or standard membrane 
feeding of Anopheles on adult volunteer blood drawn 
post-administration. This will enable an assessment of 
the well-tolerated dose range, which can be further con-
firmed in safety and tolerability studies of the new com-
pound in combination with SP–AQ in adult healthy 
volunteers. This will also enable mosquito population 
modelling, to estimate the compound doses that will 
exceed a hazard ratio (HR) of 4 for 30 days (to allow co-
administration with a SMC that is given every 4 weeks) 
and thus inform the potential therapeutic dose range to 
test in Phase II studies (starting in adults, and de-escalat-
ing in age to reach the target population). A food-effect 
study will also be required, since, optimally, there should 
be no food effect for this drug. In parallel with this Phase 
I study, it would be important to start the early embryo 
fetal development studies in rats and rabbits and other 
standard genotoxic and safety pharmacology studies. In 
the event of a safety signal, this would down-prioritize 
the use of such a molecule in women of unknown preg-
nancy status, and thus affect reaching the longer-term 
MDA goal, although it would not prevent continued 
development for SMC. Given the use in combination, 
drug–drug interaction studies may be necessary with 
any drugs for use in SMC, based on the outcome of Sim-
Cyp simulations [77] and in vitro drug–drug interaction 
assessments.
Phase II and Phase III study designs
Phase II and Phase III studies will be carried out in the 
sub-Sahel regions, in which SMC with SP–AQ is well 
established in children who are asymptomatic, and hence 
may be either parasite-free or have sub-clinical P. falci-
parum infection (symptomatic patients are treated with 
the local standard of care anti-malarial combination). 
The objectives of these studies are to confirm good safety 
or tolerability by cautious age de-escalation, to reach the 
target extended SMC population of 5–10 years, and even-
tually, if possible, to descend to the 6  months–5  years 
range. The ultimate goal is to demonstrate superior effi-
cacy of TCP-6 plus SP–AQ compared with SP–AQ alone 
(in Phase III).
The primary efficacy endpoint will be the cumulative 
incidence rate reduction (IRR) of symptomatic malaria 
cases, however secondary endpoints, such as asexual par-
asite prevalence and additional supportive entomological 
endpoints could include, for example: parity rate, mos-
quito density, or the 3-day survival of caught mosquitoes.
Depending on the interactions with the Stringent Reg-
ulatory Authorities, this package up to Phase III could 
potentially lead to registration. A proposed Phase IV 
study will be a cluster randomized study to demonstrate, 
Fig. 5 Draft TCP-6 clinical development plan for a novel TCP-6 added to SP–AQ for seasonal malaria chemoprevention in asymptomatic 
subjects < 10 years of age. *West and Central Africa as required: Burkina Faso, Cameroun, Chad, Gambia, Ghana, Guinea, Guinea Bissau, Niger, 
Nigeria, Mali, Senegal, Togo; **Excluding women of child-bearing potential; SAD, Single ascending dose study; SMFA, Standard membrane feeding 
assay; MAD, multiple ascending dose study; SP–AQ, sulfadoxine–pyrimethamine
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as for Phase III, statistical superior IRR of symptomatic 
malaria cases of TCP-6 plus SP–AQ versus SP–AQ 
alone, and also to measure an effect on the total human 
population, rather than just those treated on population 
prevalence of symptomatic malaria cases, positive para-
sitaemia and gametocytes, to demonstrate an impact on 
transmission. Theoretically, the population evaluated in 
this study could be expanded to subjects > 10 years of age.
Conclusions
The continued drive towards malaria elimination 
requires a combination of better and more extensive 
deployment of existing tools, and the development of 
new ones. One area that has been discussed frequently is 
the specific application of transmission-reduction tools. 
Much of the focus in the past has been on vector control 
through ITNs and IRS, transmission-blocking vaccines, 
or the deployment of single, low-dose primaquine. The 
additional approach of using an endectocide to deliver a 
lethal dose of drug to the insect has received less atten-
tion, but this is changing with recent work on avermec-
tins and isoxazolines.
Whether or not ivermectin is ultimately deployed, 
there is still a role for new compounds, either improving 
on safety, convenience and ease of use, or to help target 
emerging resistance in the insect vectors. To help con-
ceptualize this, a TCP for a new chemical entity target-
ing the insect vector has been developed here: TCP-6. 
This lays out the key issues in terms of drug discovery 
and lead optimization, knowing that the work here is 
at the interface of traditional drug discovery and vector 
control. Using this framework, a screening cascade was 
developed which can help support a logical progression 
of compounds towards a clinical candidate.
The clinical development pathway for such a transmis-
sion-reducing agent is complicated, in that there is no 
precedent, and hence a constant dialogue with the regu-
latory authorities and the WHO will be essential. Several 
use cases have been established, but the addition of a new 
endectocide to SMC has a certain attraction as an initial 
approach. First, it does not require the early generation of 
evidence for safety in the first, second or third trimester 
of pregnancy. Second, although the modelling suggests 
that as large a population as possible should be targeted, 
even targeting those up to the ages of 5 and 10 is pre-
dicted to produce a significant decrease in the incidence 
and prevalence of infection. Modelling also suggests that 
dosing and human pharmacokinetics must produce a HR 
of 4 that is maintained up to 30 days.
This definition comes at an important time. The 
last few years of vector control have been focused on 
insecticides that work for LLINs, and thus are effective 
because of direct physical contact. Recently there has 
been an increased interest in ATSBs that deliver the 
insecticide to the mosquito by ingestion. The overlap 
between the requirements for a compound active as 
an ATSB and one active for endectocide transmission 
blocking are significant. This synergy gives renewed 
optimism that such compounds can be identified and 
developed.
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